[go: up one dir, main page]

AR104280A1 - Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos - Google Patents

Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos

Info

Publication number
AR104280A1
AR104280A1 ARP160101027A ARP160101027A AR104280A1 AR 104280 A1 AR104280 A1 AR 104280A1 AR P160101027 A ARP160101027 A AR P160101027A AR P160101027 A ARP160101027 A AR P160101027A AR 104280 A1 AR104280 A1 AR 104280A1
Authority
AR
Argentina
Prior art keywords
coagulation factor
antigen binding
binding site
chain
binds
Prior art date
Application number
ARP160101027A
Other languages
English (en)
Inventor
Lechner Katharina
Calatzis Andreas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52997894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR104280A1 publication Critical patent/AR104280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un anticuerpo multiespecífico que comprende un primer sitio de unión a antígeno que se une al factor de coagulación IX y/o al factor de coagulación IX activado y un segundo sitio de unión a antígeno que se une al factor de coagulación X, para su uso en el tratamiento de la hemofilia A, en el que el anticuerpo se usa en combinación con un factor de coagulación IX. Reivindicación 4: Un factor de coagulación IX para su uso en el tratamiento de un paciente que padece a) deficiencia o b) mal funcionamiento del factor de coagulación VIII, en el que el factor de coagulación IX se usa en combinación con un anticuerpo multiespecífico que comprende un primer sitio de unión a antígeno que se une al factor de coagulación IX y/o al factor de coagulación IX activado y un segundo sitio de unión a antígeno que se une al factor de coagulación X. Reivindicación 19: La combinación, el anticuerpo o el uso de acuerdo con una cualquiera de las reivindicaciones precedentes, en el que el anticuerpo es biespecífico y el primer sitio de unión a antígeno que se une al factor de coagulación IX y/o al factor de coagulación IX activado comprende secuencias de aminoácidos de CDR 1, 2 y 3 de cadena H de SEQ ID Nº 105, 106, y 107 (las CDR de cadena H de Q499), respectivamente y secuencias de aminoácidos de CDR 1, 2 y 3 de cadena L de SEQ ID Nº 156, 157, y 158 (las CDR de cadena L de L404), respectivamente, y el segundo sitio de unión a antígeno comprende secuencias de aminoácidos de CDR 1, 2 y 3 de cadena H de SEQ ID Nº 126, 127 y 128 (las CDR de cadena H de J327), respectivamente y secuencias de aminoácidos de CDR 1, 2 y 3 de cadena L de SEQ ID Nº 156, 157, y 158 (las CDR de cadena L de L404), respectivamente.
ARP160101027A 2015-04-17 2016-04-15 Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos AR104280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15164045 2015-04-17

Publications (1)

Publication Number Publication Date
AR104280A1 true AR104280A1 (es) 2017-07-12

Family

ID=52997894

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101027A AR104280A1 (es) 2015-04-17 2016-04-15 Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos

Country Status (13)

Country Link
US (3) US20180244798A1 (es)
EP (1) EP3283099B1 (es)
JP (1) JP6698102B2 (es)
KR (1) KR102057767B1 (es)
CN (1) CN107454906B (es)
AR (1) AR104280A1 (es)
AU (1) AU2016248817A1 (es)
BR (1) BR112017016952A2 (es)
CA (1) CA2978038A1 (es)
HK (1) HK1244493A1 (es)
IL (1) IL253658A0 (es)
MX (1) MX2017010734A (es)
WO (1) WO2016166014A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
KR102560808B1 (ko) 2016-09-06 2023-07-27 추가이 세이야쿠 가부시키가이샤 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법
WO2018098363A2 (en) * 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
AU2018216008A1 (en) * 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
CN110461358A (zh) * 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
WO2019096874A1 (en) 2017-11-15 2019-05-23 Novo Nordisk A/S Factor x binders enhancing fx activation
FR3082427B1 (fr) * 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
SG11202100418PA (en) * 2018-08-01 2021-02-25 Novo Nordisk As Improved procoagulant antibodies
WO2020114614A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Proteinaceous molecules binding factor ixa and factor x
WO2020115281A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Proteinaceous molecules binding factor ixa and factor x
WO2020115283A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
WO2020114615A1 (en) * 2018-12-07 2020-06-11 Baxalta GmbH Bispecific antibodies binding factor ixa and factor x
BR112021012065A2 (pt) 2018-12-21 2021-12-07 Kymab Ltd Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia
WO2024225440A1 (ja) * 2023-04-28 2024-10-31 公立大学法人奈良県立医科大学 血友病ａを有する対象の処置のための、活性化凝固第ｉｘ因子及び凝固第ｘ因子と結合する二重特異性抗体と血液凝固第ｘ因子の併用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614500A (en) 1983-03-04 1997-03-25 The Scripps Research Institute Compositions containing highly purified factor IX proteins prepared by immunoaffinity chromatography
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
NZ288883A (en) * 1994-07-11 1998-12-23 Univ Texas Conjugates comprising coagulation factors
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
EP1356075A4 (en) 2000-10-16 2005-04-13 Compound Therapeutics Inc PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
JP5037331B2 (ja) * 2004-03-19 2012-09-26 バクスター・インターナショナル・インコーポレイテッド 出血性障害の処置のための第ｉｘａ因子
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
EP1876236B9 (en) 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
WO2007101681A1 (en) 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
PH12013500974A1 (en) * 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii

Also Published As

Publication number Publication date
IL253658A0 (en) 2017-09-28
CN107454906A (zh) 2017-12-08
JP2018513163A (ja) 2018-05-24
EP3283099A1 (en) 2018-02-21
MX2017010734A (es) 2017-12-04
CA2978038A1 (en) 2016-10-20
US20220119550A1 (en) 2022-04-21
KR102057767B1 (ko) 2019-12-19
WO2016166014A1 (en) 2016-10-20
KR20170125977A (ko) 2017-11-15
EP3283099B1 (en) 2022-03-02
BR112017016952A2 (pt) 2018-04-03
CN107454906B (zh) 2022-05-27
HK1244493A1 (zh) 2018-08-10
JP6698102B2 (ja) 2020-05-27
US20180244798A1 (en) 2018-08-30
US20240239917A1 (en) 2024-07-18
AU2016248817A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
AR104280A1 (es) Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
PH12021550023A1 (en) Humanized anti-tau antibodies
CL2018000502A1 (es) Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer.
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
PE20190737A1 (es) Anticuerpos anti-cd27
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
EA201791093A1 (ru) Антитела к cd47, способы и применение
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CL2017002614A1 (es) Método para la purificación de proteínas
EA202092302A1 (ru) Антитела к trem-1 и их применения
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
PE20180691A1 (es) Variantes de il-37
PE20191743A1 (es) Anticuerpos biespecificos anti-pd-l1-anti-tim3
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b

Legal Events

Date Code Title Description
FB Suspension of granting procedure